Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
83 hedge funds and large institutions have $111M invested in Viracta Therapeutics, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 17 reducing their positions, and 11 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 17
61% more call options, than puts
Call options by funds: $5.31M | Put options by funds: $3.3M
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
6% more funds holding
Funds holding: 78 → 83 (+5)
2% less capital invested
Capital invested by funds: $113M → $111M (-$1.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$4.2M |
| 2 |
VAM
Visium Asset Management
New York
|
+$3.54M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.12M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.5M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$1.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.93M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$2.99M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.06M |
| 4 |
First Eagle Investment Management
New York
|
-$1.99M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.99M |
VIRX Hedge Fund Activity: Q1 2015 in Review
83 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2015, worth a combined $111M — down 1.6% from $113M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new VIRX positions and 11 closed out — a net gain of 5 holders — while 32 added to existing stakes and 17 trimmed.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $4.2M. The largest seller was Citadel Advisors, cutting an estimated $5.93M.
- 83 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2015, up from 78 in Q4 2014.
- Funds reported $111M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2015, down 1.6% quarter-over-quarter.
- 16 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2015 and 11 closed out, a net change of +5 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2015 was Ghost Tree Capital, an estimated $4.2M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2015 was Citadel Advisors, an estimated $5.93M sold.
Based on aggregated 13F filings for Q1 2015.